These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 24380871)

  • 1. In vivo monitoring of sorafenib therapy effects on experimental prostate carcinomas using dynamic contrast-enhanced MRI and macromolecular contrast media.
    Cyran CC; Schwarz B; Paprottka PM; Sourbron S; von Einem JC; Dietrich O; Hinkel R; Clevert DA; Bruns CJ; Reiser MF; Nikolaou K; Wintersperger BJ
    Cancer Imaging; 2013 Dec; 13(4):557-66. PubMed ID: 24380871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic contrast-enhanced computed tomography imaging biomarkers correlated with immunohistochemistry for monitoring the effects of sorafenib on experimental prostate carcinomas.
    Cyran CC; von Einem JC; Paprottka PM; Schwarz B; Ingrisch M; Dietrich O; Hinkel R; Bruns CJ; Clevert DA; Eschbach R; Reiser MF; Wintersperger BJ; Nikolaou K
    Invest Radiol; 2012 Jan; 47(1):49-57. PubMed ID: 21934514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perfusion MRI for monitoring the effect of sorafenib on experimental prostate carcinoma: a validation study.
    Cyran CC; Paprottka PM; Schwarz B; Sourbron S; Ingrisch M; von Einem J; Pietsch H; Dietrich O; Hinkel R; Bruns CJ; Reiser MF; Wintersperger BJ; Nikolaou K
    AJR Am J Roentgenol; 2012 Feb; 198(2):384-91. PubMed ID: 22268182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a novel macromolecular cascade-polymer contrast medium for dynamic contrast-enhanced MRI monitoring of antiangiogenic bevacizumab therapy in a human melanoma model.
    Cyran CC; Fu Y; Rogut V; Chaopathomkul B; Wendland MF; Shames DM; Brasch RC
    Acad Radiol; 2013 Oct; 20(10):1256-63. PubMed ID: 24029057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as Imaging Biomarker for Vascular Normalization Effect of Infigratinib in High-FGFR-Expressing Hepatocellular Carcinoma Xenografts.
    Tran A; Koh TS; Prawira A; Ho RZW; Le TBU; Vu TC; Hartano S; Teo XQ; Chen WC; Lee P; Thng CH; Huynh H
    Mol Imaging Biol; 2021 Feb; 23(1):70-83. PubMed ID: 32909245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DCE-MRI biomarkers for monitoring an anti-angiogenic triple combination therapy in experimental hypopharynx carcinoma xenografts with immunohistochemical validation.
    Sterzik A; Paprottka PM; Zengel P; Hirner H; Roßpunt S; Eschbach R; Moser M; Havla L; Ingrisch M; Mack B; Reiser MF; Nikolaou K; Cyran CC
    Acta Radiol; 2015 Mar; 56(3):294-303. PubMed ID: 24609871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring anti-angiogenic therapy in colorectal cancer murine model using dynamic contrast-enhanced MRI: comparing pixel-by-pixel with region of interest analysis.
    Haney CR; Fan X; Markiewicz E; Mustafi D; Karczmar GS; Stadler WM
    Technol Cancer Res Treat; 2013 Feb; 12(1):71-8. PubMed ID: 22905809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of tumor angiogenesis with dynamic contrast-enhanced MRI and biodegradable macromolecular contrast agents in mice.
    Feng Y; Jeong EK; Mohs AM; Emerson L; Lu ZR
    Magn Reson Med; 2008 Dec; 60(6):1347-52. PubMed ID: 19025902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contrast-Enhanced Ultrasound with VEGFR2-Targeted Microbubbles for Monitoring Regorafenib Therapy Effects in Experimental Colorectal Adenocarcinomas in Rats with DCE-MRI and Immunohistochemical Validation.
    Eschbach RS; Clevert DA; Hirner-Eppeneder H; Ingrisch M; Moser M; Schuster J; Tadros D; Schneider M; Kazmierczak PM; Reiser M; Cyran CC
    PLoS One; 2017; 12(1):e0169323. PubMed ID: 28060884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of early therapeutic response to sorafenib in renal cell carcinoma xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging.
    Jeon TY; Kim CK; Kim JH; Im GH; Park BK; Lee JH
    Br J Radiol; 2015 Sep; 88(1053):20150163. PubMed ID: 26133222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnetic resonance imaging assays for dimethyl sulfoxide effect on cancer vasculature.
    Cyran CC; Sennino B; Chaopathomkul B; Fu Y; Rogut V; Shames DM; Wendland MF; McDonald DM; Brasch RC
    Invest Radiol; 2008 May; 43(5):298-305. PubMed ID: 18424950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma.
    Flaherty KT; Rosen MA; Heitjan DF; Gallagher ML; Schwartz B; Schnall MD; O'Dwyer PJ
    Cancer Biol Ther; 2008 Apr; 7(4):496-501. PubMed ID: 18219225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of perfusion MRI and 18F-FDG PET imaging biomarkers for monitoring regorafenib therapy in experimental colon carcinomas with immunohistochemical validation.
    Eschbach RS; Fendler WP; Kazmierczak PM; Hacker M; Rominger A; Carlsen J; Hirner-Eppeneder H; Schuster J; Moser M; Havla L; Schneider MJ; Ingrisch M; Spaeth L; Reiser MF; Nikolaou K; Cyran CC
    PLoS One; 2015; 10(2):e0115543. PubMed ID: 25668193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma.
    Marzola P; Degrassi A; Calderan L; Farace P; Nicolato E; Crescimanno C; Sandri M; Giusti A; Pesenti E; Terron A; Sbarbati A; Osculati F
    Clin Cancer Res; 2005 Aug; 11(16):5827-32. PubMed ID: 16115922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decrease in tumor apparent permeability-surface area product to a MRI macromolecular contrast medium following angiogenesis inhibition with correlations to cytotoxic drug accumulation.
    Daldrup-Link HE; Okuhata Y; Wolfe A; Srivastav S; Øie S; Ferrara N; Cohen RL; Shames DM; Brasch RC
    Microcirculation; 2004; 11(5):387-96. PubMed ID: 15280064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.
    Chang YS; Adnane J; Trail PA; Levy J; Henderson A; Xue D; Bortolon E; Ichetovkin M; Chen C; McNabola A; Wilkie D; Carter CA; Taylor IC; Lynch M; Wilhelm S
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):561-74. PubMed ID: 17160391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.
    Kelly RJ; Rajan A; Force J; Lopez-Chavez A; Keen C; Cao L; Yu Y; Choyke P; Turkbey B; Raffeld M; Xi L; Steinberg SM; Wright JJ; Kummar S; Gutierrez M; Giaccone G
    Clin Cancer Res; 2011 Mar; 17(5):1190-9. PubMed ID: 21224376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
    Hahn OM; Yang C; Medved M; Karczmar G; Kistner E; Karrison T; Manchen E; Mitchell M; Ratain MJ; Stadler WM
    J Clin Oncol; 2008 Oct; 26(28):4572-8. PubMed ID: 18824708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of dynamic contrast-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for evaluation of the effects of sorafenib in a rat model of hepatocellular carcinoma.
    Muñoz NM; Minhaj AA; Maldonado KL; Kingsley CV; Cortes AC; Taghavi H; Polak U; Mitchell JM; Ensor JE; Bankson JA; Rashid A; Avritscher R
    Magn Reson Imaging; 2019 Apr; 57():156-164. PubMed ID: 30465870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib.
    Kang HC; Tan KS; Keefe SM; Heitjan DF; Siegelman ES; Flaherty KT; O'Dwyer PJ; Rosen MA
    AJR Am J Roentgenol; 2013 Jan; 200(1):120-6. PubMed ID: 23255750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.